Advanced kidney carcinoma: decision paths and therapeutic perspectives
DOI:
https://doi.org/10.7175/cmi.v8i3.916Keywords:
Renal carcinoma, Oncology, Antiangiogenic therapy, Tyrosin kinase inhibitorsAbstract
Treatment of kidney cancer represents an open challenge for scientists and clinicians. In fact,renal tumours are resistant to virtually all of the currently available chemotherapeutics, beingonly partially sensitive to immunological agents. During the last decade, knowledge of geneticbasis of cancer has grown considerably. This has lead to an authentic revolution in the clinicalmanagement of renal tumours: the introduction of targeted therapies. Novel agents addressangiogenic signalling pathways through inhibition of the vascular endothelial growth factor(VEGF) or the mammalian target of rapamycin (mTOR). However, there is still no greatevidence favouring one drug over the others. This underlines the need for decision-making toolsin renal cell cancer treatment, in order to rationalise the choice of appropriate targeted agentsand to enable individualised clinical management. This is a brief overview on the state of theart of the treatment of metastatic renal tumour.
References
Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-17; http://dx.doi.org/10.1016/S0022-5347(05)67889-5
Mattei J, da Silva RD, Sehrt D, et al. Targeted therapy in metastatic renal carcinoma. Cancer Lett 2014; 343: 156-60; http://dx.doi.org/10.1016/j.canlet.2013.09.038
Fojo AT, Shen DW, Mickley LA, et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922-7
AIOM/AIRTUM. I numeri del cancro in Italia. 2013. Disponibile all’indirizzo http://www.registri-tumori.it/PDF/AIOM2013/I_numeri_del_cancro_2013.pdf (ultimo accesso settembre 2014)
Kim SP, Murad MH, Thompson RH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012; 188: 51-7; http://dx.doi.org/10.1016/j.juro.2012.03.006
Tan H-J, Norton EC, Ye Z, et al. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012; 307: 1629-35; http://dx.doi.org/10.1001/jama.2012.475
Abara E, Chivulescu I, Clerk N, et al. Recurrent renal cell cancer: 10 years or more after nephrectomy. Can Urol Assoc J 2010; 4: E45-E49
Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 2008; 35: 581-92; http://dx.doi.org/10.1016/j.ucl.2008.07.005
Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5; http://dx.doi.org/10.1038/20459
Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009; 104: 1585-9; http://dx.doi.org/10.1111/j.1464-410X.2009.08987.x
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11; http://dx.doi.org/10.1016/S0140-6736(07)61904-7
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24; http://dx.doi.org/10.1056/NEJMoa065044
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8; http://dx.doi.org/10.1200/JCO.2009.23.9764
Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res 2010; 16: 5923-7; http://dx.doi.org/10.1158/1078-0432.CCR-10-0728
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12; http://dx.doi.org/10.1200/JCO.2005.03.6723
Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007; 67: 1257-64; http://dx.doi.org/10.2165/00003495-200767090-00002
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34; http://dx.doi.org/10.1056/NEJMoa060655
Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013; 108: 311-8; http://dx.doi.org/10.1038/bjc.2012.543
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-9; http://dx.doi.org/10.1016/S0140-6736(11)61613-9
Verzoni E, Grassi P, Testa I, et al. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics Pers Med 2014; 7: 107-16
Motzer BRJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell. J Clin Oncol 2002; 20: 289-96; http://dx.doi.org/10.1200/JCO.20.1.289
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81; http://dx.doi.org/10.1056/NEJMoa066838
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56; http://dx.doi.org/10.1016/S0140-6736(08)61039-9
Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-90; http://dx.doi.org/10.1056/NEJMra043172
Albiges L, Molinie V, Escudier B. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? Oncologist 2012; 17: 1051-62; http://dx.doi.org/10.1634/theoncologist.2012-0038
Kroeger N, Xie W, Lee J-L, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119: 2999-3006; http://dx.doi.org/10.1002/cncr.28151
Patard J-J, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-71; http://dx.doi.org/10.1200/JCO.2005.07.055
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9; http://dx.doi.org/10.1200/JCO.2008.21.4809
Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. European Association of Urology, 2014. Disponibile all’indirizzo http://www.uroweb.org/gls/pdf/10%20Renal%20Cell%20Carcinoma_LR.pdf (ultimo accesso settembre 2014)
Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117: 501-9; http://dx.doi.org/10.1002/cncr.25452
Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011; 22: 295-300; http://dx.doi.org/10.1093/annonc/mdq342
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-31; http://dx.doi.org/10.1056/NEJMoa1303989
Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32: 1412-8; http://dx.doi.org/10.1200/JCO.2013.50.8267
Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-32; http://dx.doi.org/10.1200/JCO.2003.02.122
McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med Oncol 2009; 26 (Suppl 1): 13-7; http://dx.doi.org/10.1007/s12032-008-9152-1
Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-9; http://dx.doi.org/10.1007/s12032-009-9177-0
Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63; http://dx.doi.org/10.1016/S1470-2045(09)70162-7
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)